**FIRST YEAR EXPERIENCE OF A NEW TAVR SITE: WHAT IS THE DURATION OF THE TAVR LEARNING CURVE ?**

**G.A Rogers**, E. Kaluski, S. Sattur, F. Reitknecht, D. Sporn

Guthrie Health Systems, Sayre, PA, USA

*Aim*: In order to assess our initial TAVR outcomes we compared our single center first year TAVR experience to that of the USA STS registry.

*Methods*: We prospectively recorded and analyzed TAVR data at our center and compared it to the STS database for the same period of time.

*Results*: A total 41 patients underwent TAVR. Mean age 79 (58-93), 56% were male, mean STS score was 7.4 ± 3.6% (range 1.2-13.4). Devices: Sapien XT 80% and CoreValve 20%. Procedural success was 97.5%. 30-day mortality, stroke and vascular complications were 0%. Mean length of stay was 6 ± 3 days (range 3-15), 1 year mortality was 2.5%. Following TAVR 76% of patients were discharged to home with a 1 year readmission rate of 7.3%. Conclusion: With appropriate proctoring and industry guidance new centers can execute TAVR exceptionally well with a very short learning curve.

Guthrie Registry(n=41) STS Registry (n=150,000)

Age (mean ) 79 81

Males (%) 56.1 53.7

STS mortality (%) 7.4 7

Trans-femoral access (%) 88 76

Complications & outcomes

Mortality @ 30 days (%) 0 7

Mortality @ 1 year (%) 2.4 23.7

Stroke @ 1 year (%) 0 4.1

Vascular complications (%) 0 4.4

Renal failure (%) 0 1.6

Pacemaker implantation (%)14.63 11.6

Hospital stay (mean days) 6.3 7.5

Readmission @ 1 year (%) 7.3% 24%